ArticleJAC-antimicrobial resistance2025
Quality of different brands of clarithromycin tablets marketed in Ethiopia; implications for the future.
Article in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There are concerns with the availability of substandard antibiotics across Africa, including Ethiopia, exacerbating high levels of antimicrobial resistance (AMR). There are ongoing initiatives across Africa to reduce their availability to reduce AMR, including Pan-African registration, coordination with Interpol, and increasing surveillance. Consequently, the objective of the study was to evaluate the quality of different brands of clarithromycin tablets currently marketed in Ethiopia as a key antibiotic. Methods: A total of 120 tablets of 12 different brands of clarithromycin 500 mg tablets were purchased from 12 different community pharmacies. Quality control tests, including visual inspection, thickness, diameter, hardness, friability, weight variation, disintegration, dissolution, and assays, were conducted at the Ethiopian Pharmaceutical Company's drug quality control laboratory on the sourced tablets. Tests were performed in accordance with the United States Pharmacopoeia (USP) and the World Health Organization's procedures. Results: The identification test results confirmed the presence of the active pharmaceutical ingredients. The weight variation tests showed compliance with the USP limits. All clarithromycin brands and tablets met the USP requirements for hardness and disintegration times. The percentage content of all brands and tablets ranged from 95.14% to 100.44%, meeting the USP specifications. The dissolution tests also met required USP limits alongside factor (f1) factor (f2) values, which were within acceptable ranges. Conclusion: As a result, all tested clarithromycin brands conformed with the required quality standards and were of acceptable quality. Consequently, these different brands of clarithromycin can be used to effectively treat patients and support ongoing national efforts to ensure antibiotic quality and strengthen AMR containment strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.